#VisualAbstract: Pyrotinib plus capecitabine improves progression-free survival in HER2⁺ metastatic breast cancer
Click to read the study in The Lancet Oncology.
Click to read the study in The Lancet Oncology.
Click to read the study in The Lancet Oncology.
1. In this prospective cohort study, first-degree family history of breast cancer was associated with increased risk of breast cancer ...
1. Patients with previously untreated estrogen receptor ER positive (ER+), human epidermal growth factor receptor 2 (HER2) negative breast cancer ...
1. This randomized, open label, phase 3 trial found that dose-dense adjuvant chemotherapy did not significantly improve breast cancer recurrence-free ...
1. In women with early stage breast cancer and discordant genomic and clinical risk, the 5-year survival rate without distant ...
1. Extended-use adjuvant letrozole therapy was associated with significant reduction in breast cancer-free survival but not overall survival, compared to ...
1. The addition of veliparib-carboplatin to standard therapy in treating triple-negative breast cancer patients showed higher rates of pathological complete ...
1. Daughters of mothers with a family history of breast cancer or familial BRCA1/2 mutation (BCFH+) had better psychosocial adjustment ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.